医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NEC Publishes Design Blueprints for SARS-CoV-2 Vaccines Using Its Artificial Intelligence Technology

2020年04月23日 AM10:00
このエントリーをはてなブックマークに追加


 

TOKYO

NEC Corporation (NEC; TOKYO: 6701) today announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines that can drive potent T-cell responses in the majority of the global population. This initiative by the scientific teams within the NEC Group to help combat outbreaks of COVID-19 and support international vaccine development efforts is led by NEC OncoImmunity (NOI) in collaboration with NEC Laboratories Europe (NLE). These AI prediction platforms are based on the AI technology used by NEC and NOI in the development of personalized neoantigen cancer vaccines.

During the analysis, which is published at bioRxiv, the team analyzed thousands of sequences from the SARS-CoV-2 virus (responsible for causing COVID-19) and identified epitopes (potential vaccine targets) for the 100 most frequent HLA alleles (diverse immunological makeup) in the global population.

The analysis demonstrates the significant capabilities of the NEC Group to leverage their AI platforms to design blueprints for a vaccine that is safe and efficacious in a global population and could address the current and future divergent strains of the SARS-CoV-2 virus.

NEC is now publishing this research to support scientific advancements in the field and is ready to start partnering efforts to pursue the development of an effective vaccine targeting the global population.

“As a company that seeks to enhance the well-being of society, NEC will continue to capitalize on research and development that maximizes the strengths of our AI technology to help prevent the spread of COVID-19. In collaboration with companies and institutions around the world, we aim to enable people to live their daily lives with as much safety and security as possible,” said Motoo Nishihara, Executive Vice President and Chief Technology Officer at NEC.

“It has been exhilarating work to adapt our NEC Immune Profiler technology from its current cancer focus and quickly make it applicable to infectious diseases to help deal with the COVID-19 threat. It is encouraging that our AI and bioinformatics platform can design vaccine blueprints that have the potential to induce a broad immune response, that may not only be protective for the global population, but also stimulate a long-lived memory immune responses against SARS-CoV-2 and its future mutated versions,” said Dr. Trevor Clancy, Chief Scientific Officer at NEC OncoImmunity and the lead corresponding author in the paper.

“We have been repurposing our algorithms originally designed for predicting immune responses in individual cancer patients to scale to large population targets for infectious diseases. Now demonstrating that our predictions can contribute to the worldwide efforts to stop COVID-19 is of utmost importance. This is an important step towards the development of an effective vaccine to stop COVID-19 for the global population,” said Dr. Saverio Niccolini, General Manager of the Data Science and System Platform Division at NEC Laboratories Europe GmbH.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200422006099/en/

CONTACT

Joseph Jasper, j-jasper(at)nec.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • MetLife’s 360Health Wins Gold Stevie®
  • PHC株式会社:配薬支援および決済サービスを実現した「ヘルスケア手帳」サービスを導入-患者さんへの医療サービス向上を目指したクラウドサービス連携ソリューション「Medicom Cloudコネクト」第一弾
  • iProov Partners with IDV Pacific to Enhance Online Identity Verification in Australia and New Zealand
  • MedTech Innovator Selects 20 Startups for Annual Asia Pacific Accelerator and Announces Extended Asia Pacific Partnership With Johnson & Johnson
  • IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020